Hepatitis C Virus Infection and Immunomodulatory Therapies

Clinics in Liver Disease

Volumn 13, Issue 3, 2009, Pages 391-401

  Forde, Kimberly A ^a,b   Reddy, K Rajender ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b School of Veterinary Medicine   (United States)

Author keywords

Hepatitis C infection; Immune modulators; Therapy

Indexed keywords

ALBINTERFERON; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ANTIVIRUS AGENT; BAVITUXIMAB; BELEROFON; BETA INTERFERON; BLX 883; CHRONVAC C; CIGB 230; GAMMA INTERFERON; GI 5005; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; IC 41; INTERFERON; ISATORIBINE; LOCTERON; MAXY ALPHA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HCV AB68; NITAZOXANIDE; OMEGA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON LAMBDA; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TARIBAVIRIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL ACTIVITY; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOPENIA; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; MYALGIA; NAUSEA; NONHUMAN; REVIEW; SKIN DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS RESISTANCE; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERONS; RIBAVIRIN; THIAZOLES; TOLL-LIKE RECEPTORS; VIRAL HEPATITIS VACCINES;

EID: 67650523019     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.05.007     Document Type: Review

References (51)

1. World Health Organization (WHO). Hepatitis C. Available at:. http://www.who.int/mediacentre/factsheets/fs164/en/index.html Accessed March 1, 2009
2. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
3. Balogun M.A., Ramsay M.E., Hesketh L.M., et al. The prevalence of hepatitis C in England and Wales. J Infect 45 (2002) 219-226
4. Mutimer D.J., Harrison R.F., O'Donnell K.B., et al. Hepatitis C virus infection in the asymptomatic British blood donor. J Viral Hepat 2 (1995) 47-53
5. Booth J.C., Brown J.L., and Thomas H.C. The management of chronic hepatitis C virus infection. Gut 37 (1995) 449-454
6. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 26 (1997) 15S-20S
7. Liang T.J., Rehermann B., Seeff L.B., et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132 (2000) 296-305
8. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (2002) S74-S83
9. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346 (1995) 1051-1055
10. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 351 (1998) 1535-1539
11. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
12. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
13. Muir A.J., Bornstein J.D., and Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350 (2004) 2265-2271
14. Rodriguez-Torres M., Jeffers L.J., Sheikh M.Y., et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 360 (2009) 257-267
15. Bressler B.L., Guindi M., Tomlinson G., et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 (2003) 639-644
16. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
17. Romero-Gomez M., Diago M., Andrade R.J., et al. Metformin with peginterferon alfa-2a and ribavirin in the treatment of naive genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final results of a randomized and double-blinded trial [abstract LB6]. Hepatology 48 Suppl 1 (2008) 380A
18. Conjeevaram H.S., Burant C.F., McKenna B., et al. A randomized, double-blind, placebo-controlled study of PPAR-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. [abstract]. Hepatology 48 Suppl 1 (2008) 384A
19. Elgouhari H.M., Cesario K.B., Lopez R., et al. Pioglitazone improves early virologic kinetic response to Peg IFN/RBV combination therapy in hepatitis C genotype 1 naïve patients. [abstract]. Hepatology 48 Suppl 1 (2008) 383A
20. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
21. Tompkins W.A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 19 (1999) 817-828
22. Brunton L.L. Goodman and Gilman's the pharmacologic basis of therapeutics (2006), The McGraw-Hill Companies; USA
23. Subramanian G.M., Fiscella M., Lamouse-Smith A., et al. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 25 (2007) 1411-1419
24. Zeuzem S., Yoshida E.M., Benhamou Y., et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 48 (2008) 407-417
25. Rustgi V.K. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 25 4 (2009) 991-1002
26. De Leede L.G., Humphries J.E., Bechet A.C., et al. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res 28 (2008) 113-122
27. Dzyublyk I., Yegorova T., Moroz L., et al. Phase 2a study to evaluate the safety and tolerability and anti-viral of 4 doses of a novel, controlled-release interferon alfa-2b (Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with chronic hepatitis C (genotype 1) [abstract LB10]. Hepatology 46 Suppl 1 (2007) 863A
28. Lawitz E., Zaman A., Muir A., et al. Interim results from a phase 1b dose-escalation study of 4 weeks of peg-interferon lambda (PEG-RIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin [abstract 170]. Hepatology 48 Suppl 1 (2008) 385A
29. Novozhenov V., Zakharova N., Vinogradova E., et al. J.M. Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection [abstract 11]. J Hepatol 46 Suppl 1 (2007) S8
30. Kronenberger B., Welsch C., Forestier N., et al. Novel hepatitis C drugs in current trials. Clin Liver Dis 12 (2008) 529-555 viii
31. Tam R.C., Pai B., Bard J., et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 30 (1999) 376-382
32. Lin C.C., Yeh L.T., Vitarella D., et al. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 14 (2003) 145-152
33. Arora S., Xu C., Teng A., et al. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J Clin Pharmacol 45 (2005) 275-285
34. Gish R.G., Arora S., Rajender Reddy K., et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 47 (2007) 51-59
35. Marcellin P., Lurie Y., Rodrigues-Torres M., et al. The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-naive patients infected with HCV: phase 3 results [abstract 10]. J Hepatol 46 Suppl 1 (2007) S7
36. Godofsky E., and Shan J. Phase I singe dose study of bavituximab, a chimeric anti-phosphatidylserine monoclonal antibody, in subjects with chronic hepatitis C [abstract 127]. Hepatology 44 Suppl 1 (2006) 236A
37. Galun E., Terrault N.A., Eren R., et al. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 46 (2007) 37-44
38. Schiano T.D., Charlton M., Younossi Z., et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 12 (2006) 1381-1389
39. Eren R., Landstein D., Terkieltaub D., et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80 (2006) 2654-2664
40. Yu M.Y., Bartosch B., Zhang P., et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 101 (2004) 7705-7710
41. Willems J., Ede M., Marotta P., et al. Anti-HCV human immunogobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. J Hepatol 36 Suppl 1 (2002) 32 [abstract 96]
42. Davis G.L., Nelson D.R., Terrault N., et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11 (2005) 941-949
43. Sallberg M, Frelin L, Diepolder H, et al. A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C [abstract 43]. Journal of Hepatology 2009;50(Suppl 1):S18-9.
44. Schiff E., Everson G., Tsai N., et al. HCV-specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI-5005, a yeast-based immunotherapy targeting NS3 and core: a randomized, double-blind, placebo controlled phase 1B study. Hepatology 46 Suppl 1 (2007) 816A [abstract 1304]
45. Kuzushita N., Gregory S.H., Monti N.A., et al. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology 130 (2006) 453-464
46. Seki E., and Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48 (2008) 322-335
47. McHutchison J.G., Bacon B.R., Gordon S.C., et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46 (2007) 1341-1349
48. Horsmans Y., Berg T., Desager J.P., et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42 (2005) 724-731
49. Korba B.E., Montero A.B., Farrar K., et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 77 (2008) 56-63
50. Rossignol J.F., Kabil S.M., El-Gohary Y., et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28 (2008) 574-580
51. Rossignol J., Elfert A., and Keeffe E. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PEGIFN) plus NTZ for treatment of chronic hepatitis C: final report [abstract 87]. Hepatology 48 Suppl 1 (2008) 344A